Percutaneous Thermal Ablation in Lung Tumors
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Percutaneous thermal ablation of lung tumors.
- Who it may be relevant to
- Registry conditions: Lung Cancer. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Percutaneous Thermal Ablation in Treatment of Lung Cancer
Overview
Lung cancer has a high incidence globally, with Egypt having it as the third most common and most lethal cancer, affecting 16.9% of males and 3.8% of females. While surgery is the preferred treatment for stage 1 non-small cell lung cancer due to positive outcomes, it carries significant risks due to patient comorbidities. Non-invasive treatments like radio frequency ablation (RFA) and microwave ablation (MWA) are alternatives for those unable to undergo surgery. These techniques use energy to destroy tumor tissue with minimal invasiveness and can be guided by computed tomography to ensure accurate ablation.
Detailed description
The incidence of lung cancer is one of the highest in the world. In Egypt lung cancer is the third common cancer and the most lethal malignancy in egypt . Where it is responsible for 16.9% and 3.8% of all cancers in males and females respectively.
Surgery is universally accepted as the best choice of therapy in stage 1 non small lung cancer , this is based on favourable outcomes observed in patients who have been surgically treated. However surgery is often high risk procedure because of several comorbidities affecting this cohort of patients.
Therefore non invasive local treatment that makes it possible to avoid resection of functioning parenchyma or prolonged general anaethesia representa key point in management of patients who are not eligible for surgery.
The ablative technologies utilize several sources of energy and different devices to damage targeted tissue using either radio frequency ablation (RFA) or microwave ablation (MWA) which are mini-invasive procedures as they deliver energy to tumour through single or multiple percutaneous needles.
The goal of TA is to induce targeted tissue damage by heating cells to +60 celsius to obtain a complete necrosis of tumour and surrounding tissue, TA may be performed under either conscious sedation or general anaethesia to avoid pain caused by needle insertion and tissue heating.
Computed tomography is today only accurate image guidance method for lung TA, CT guarantees a direct post-procedure .evaluation of ablation, and ground glass opacity is an indicator of extent of ablation achieved to tumour
Interventions
- Radiation Percutaneous thermal ablation of lung tumors
Percutaneous radiofrequency ablation
Primary outcome measures
- Accuracy and success [Time frame: 1 year]
Eligibility criteria
Inclusion criteria
- lung cancer smaller than 5 cm
- metastasis to the lung
- patients with lung cancer and multiple comorbidities who are unfit for surgery
Exclusion criteria
- lung cancer larger than 5 cm
- lung cancer stage II or more
- patients who cannot tolerate CT guided needle placement for thermal ablation of lung tumors
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Egypt · 1 center
- Faculty of medicine — Asyut
Identifiers
NCT: NCT06891183 · Radiofrequency ablation